Pedersen B, Christiansen J
Am J Surg. 1983 Jun;145(6):788-90. doi: 10.1016/0002-9610(83)90141-1.
The prophylactic affect of dihydroergotamine-heparin (0.5 mg dihydroergotamine plus 5,000 units of heparin administered twice daily) against postoperative thromboembolic complications after gastrointestinal surgery was compared with the affect of 5,000 units of heparin administered three times daily in a controlled, randomized study. Fifty patients received the dihydroergotamine and heparin combination twice daily and 50 patients received 5,000 units of heparin three times daily. The two groups were comparable with respect to age, sex, body weight, and type of operation. The presence or absence of deep venous thrombosis in the legs was determined postoperatively by the radiofibrinogen uptake test. The frequency of deep venous thrombosis in the dihydroergotamine and heparin group was 12 percent compared with 18 percent in the heparin group (0.1 greater than p greater than 0.05). Wound hematoma developed in two patients in the heparin group and in one patient in the dihydroergotamine and heparin group (4 and 2 percent, respectively). No other hemorrhagic complications occurred. By combining heparin with dihydroergotamine it is possible to reduce the daily heparin dose by one third and still obtain the same level of prophylaxis against thromboembolism. The frequency of bleeding complications was very low in both groups, since only one wound hematoma occurred in the dihydroergotamine and heparin group and two in the heparin group.
在一项对照随机研究中,比较了双氢麦角胺 - 肝素(0.5毫克双氢麦角胺加5000单位肝素,每日给药两次)与每日三次给药5000单位肝素对胃肠道手术后血栓栓塞并发症的预防效果。50例患者每日两次接受双氢麦角胺和肝素联合治疗,50例患者每日三次接受5000单位肝素治疗。两组在年龄、性别、体重和手术类型方面具有可比性。术后通过放射性纤维蛋白原摄取试验确定腿部深静脉血栓形成的有无。双氢麦角胺和肝素组深静脉血栓形成的发生率为12%,而肝素组为18%(0.1>p>0.05)。肝素组有2例患者出现伤口血肿,双氢麦角胺和肝素组有1例患者出现伤口血肿(分别为4%和2%)。未发生其他出血并发症。通过将肝素与双氢麦角胺联合使用,可以将每日肝素剂量减少三分之一,同时仍能获得相同水平的血栓栓塞预防效果。两组出血并发症的发生率都非常低,因为双氢麦角胺和肝素组仅出现1例伤口血肿,肝素组出现2例。